According to reports in the New England Journal of Medicine on Wednesday, an experimental Ebola vaccine developed by GlaxoSmithKline produced an immune response in all 20 healthy volunteers, without any side-effects. The trial began on September 2, and will monitor the volunteers for 48 weeks, to test the drug for safety and effectiveness.